Osaic Holdings Inc. Acquires 80,518 Shares of Johnson & Johnson $JNJ

Osaic Holdings Inc. lifted its stake in Johnson & Johnson (NYSE:JNJ) by 13.2% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 691,594 shares of the company’s stock after purchasing an additional 80,518 shares during the quarter. Osaic Holdings Inc.’s holdings in Johnson & Johnson were worth $106,457,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Evolution Wealth Management Inc. bought a new position in shares of Johnson & Johnson during the second quarter valued at $27,000. Semmax Financial Advisors Inc. raised its holdings in Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares during the last quarter. GFG Capital LLC purchased a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $35,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $48,000. Finally, Vermillion & White Wealth Management Group LLC lifted its position in Johnson & Johnson by 66.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock valued at $57,000 after acquiring an additional 150 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $211.65 on Monday. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $509.93 billion, a PE ratio of 20.43, a price-to-earnings-growth ratio of 2.36 and a beta of 0.36. The firm’s 50 day moving average price is $196.09 and its 200-day moving average price is $177.42. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $212.27.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. The ex-dividend date was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Bank of America boosted their price target on Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 15th. Citigroup boosted their target price on Johnson & Johnson from $215.00 to $232.00 and gave the stock a “buy” rating in a research report on Thursday. The Goldman Sachs Group raised their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a report on Thursday, October 9th. Scotiabank initiated coverage on shares of Johnson & Johnson in a report on Thursday, November 13th. They set a “sector outperform” rating and a $230.00 price objective for the company. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. Four research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $207.55.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.